|
|
Article: Glaxo Wellcome, NeXstar Pharmaceuticals Sign Three-Part Collaboration Featuring the SELEX Process; NeXstar Licenses a Glaxo Wellcome Oncology Drug
- Article from:
- PR Newswire
- Article date:
- May 27, 1998
CopyrightCOPYRIGHT 1998 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
BOULDER, Colo., May 27 /PRNewswire/ -- NeXstar Pharmaceuticals, Inc. (Nasdaq: NXTR) and Glaxo Wellcome (London: GLXO) announced today a three-part collaboration, including a license by Glaxo Wellcome for the use of NeXstar Pharmaceuticals' proprietary SELEX drug discovery process as a research tool for target validation in Glaxo Wellcome's functional genomics programs.
The three primary components of the collaboration are:
-- Glaxo Wellcome receives a non-exclusive right to practice NeXstar
Pharmaceuticals' proprietary SELEX process for target validation;
-- NeXstar Pharmaceuticals receives the exclusive rights to develop ...